Alzheimer's
Enhanced Genomics and The ALBORADA Drug Discovery Institute Partner to Accelerate Alzheimer's Drug Discovery
Enhanced Genomics
PR-06-25-NI-08Jun 24, 2025
RWD
Unlocking the Power of Real-World Data in Long-Term Care
Jeff Wessinger
PointClickCare Life Sciences
PAO-04-25-CL-09Apr 25, 2025
Neurodegenerative Disease Clinical Trials
Preparing for Growth in Neurodegenerative Treatment Opportunities: How Clinical Teams can Best Position Study Design and Strategy to Reach Study Participants
John Hamlet; Christine Martino, MPM; Sabine Krofczik-Wilhelm, Ph.D.; Alberto Lledó, M.D., Ph.D.
PPD clinical research business of Thermo Fisher Scientific
PAO-09-022-CL-09Sep 27, 2022
Alzheimer's Diagnostic Test
FDA Permits Marketing for New Test to Improve Diagnosis of Alzheimer's Disease
U.S. Food & Drug Administration
PR-M05-22-02May 04, 2022
Column: New Drug Watch
Alzheimer Drug Still Controversial
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-022-NI-04Mar 23, 2022
Alzheimer's Vaccine
Araclon Biotech Advances in Its Innovative Vaccine and Diagnostic Test for Alzheimer's
Araclon Biotech
PR-M03-22-06Mar 15, 2022
Alzheimer's Disease
Early Targeting of Chronic Inflammation That Precedes and Causes Synaptic Loss
Raymond J. Tesi, M.D.
INmune Bio
PTV-07-21-CL-001Jul 29, 2021
FDA Approval
FDA Grants Accelerated Approval for Aduhelm™ as the First and Only Alzheimer’s Disease Treatment to Address a Defining Pathology of the Disease
Biogen
PR-M06-21-015Jun 08, 2021
Stem Cells
Changing the Paradigm of Stem Cell Technology
Sandy Solmon
Celavie Biosciences
PAP-Q4-20-CL-008Dec 09, 2020
Alzheimer's Disease
The Self-Protein Challenge
Andrea Pfeifer, Ph.D.
AC Immune
PAP-Q4-19-CL-002Dec 06, 2019
Alzheimer's Disease
Innovating the Approach to Neurological Disease Treatment
Michaela Gallagher
AgeneBio
PAP-Q4-19-CL-004Dec 06, 2019
Funding
T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease
T3D Therapeutics, Inc.
PR-M11-19-NI-001Nov 05, 2019
Prevention
Could Preventing the Development of Amyloid Beta Lesions in the Brain Stop Alzheimer’s?
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M09-19-NI-012Sep 11, 2019
Research
New Alzheimer’s Test Could be on the Horizon
Pharma's Almanac
PAO-M08-19-NI-011Aug 07, 2019
Appointment
Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments
Eisai
PR-M05-19-NI-015May 06, 2019
Research
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
ProMIS Neurosciences
PR-M03-19-NI-067Mar 25, 2019
Machine Learning
Machine Learning May Benefit Future Alzheimer’s Patients
Emilie Branch
Pharma's Almanac
PAO-M03-19-NI-022Mar 12, 2019
FDA
FDA Moves Against Companies Claiming Treatments for Alzheimer’s Disease
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M02-19-NI-013Feb 19, 2019
Alzheimer's Disease
Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
ProMIS Neurosciences
PR-M02-19-NI-001Feb 04, 2019
Alzheimer's Disease
First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials
Eisai
PR-M12-18-NI-037Dec 12, 2018